TY - JOUR T1 - Usefulness of Implementing Comprehensive Pharmaceutical Care for Metastatic Renal Cell Carcinoma Outpatients Treated with Pazopanib JF - Anticancer Research JO - Anticancer Res SP - 999 LP - 1004 DO - 10.21873/anticanres.13205 VL - 39 IS - 2 AU - MAKI TODO AU - SUGURU SHIROTAKE AU - KOSHIRO NISHIMOTO AU - YOTA YASUMIZU AU - GOU KANEKO AU - HIDEYUKI KONDO AU - TAKASHI OKABE AU - HIDEKI MAKABE AU - MASAFUMI OYAMA Y1 - 2019/02/01 UR - http://ar.iiarjournals.org/content/39/2/999.abstract N2 - Background: Pazopanib is an effective treatment option for renal cell carcinoma (RCC). However, the therapy is often limited by the appearance of adverse events (AEs), including nausea/vomiting, hepatic impairment, hand-foot syndrome, diarrhea, hypertension and oral mucositis. Early management of AEs is, therefore, extremely important in order to maximize treatment outcomes. Patients and Methods: This non-randomized controlled before-and-after study was carried out to evaluate the effectiveness of our comprehensive pharmaceutical interventions in 37 outpatients receiving pazopanib for RCC (experimental group). Data were compared with those obtained from 13 patients before the start of pharmaceutical intervention (control group). Results: The incidence rates of grade 2 or more nausea and anorexia were significantly lower in the experimental, than in the control group (3% versus 38% for nausea, respectively, p=0.003; 8% versus 46% for anorexia, respectively, p=0.005). Importantly, non-adherence based on patient self-assessment was not observed with intervention (0% versus 38%, p<0.001). Consequently, the median total dose of pazopanib was increased by the intervention (72,600 versus 18,200 mg, p=0.002). Moreover, the median time to treatment failure was significantly longer with intervention than before (10.2 versus 1.7 months, HR=0.23, 95% CI=0.110-0.499, p<0.001). These findings suggest that our interventions are highly effective for enhancing treatment outcomes. ER -